<DOC>
	<DOCNO>NCT02707926</DOCNO>
	<brief_summary>Hypothesis : Antiretroviral drug ( ARVs ) enhance LT penetration characteristic vitro macaque translate ARV regimen increase LN GALT concentration faster decay potent suppression HIV replication LT HIV-infected person . Objectives : 1 . Determine lymph node ( LN ) gut-associated lymphoid tissue ( GALT ) pharmacokinetics ( PK ) HIV-infected person antiretroviral drug ( ARV ) regimen . 2 . Determine virological response antiretroviral therapy plasma , peripheral blood mononuclear cell ( PBMCs ) lymphoid tissue ( LT ) .</brief_summary>
	<brief_title>The Lymphoid Tissue Pharmacology Antiretroviral Drugs</brief_title>
	<detailed_description>This single-center study 18 ARV naïve , HIV infect person assess impact ARV regimen lymph node ( LN ) ( GALT ) virus reservoir . All participant give inform consent . At baseline , plasma PBMCs obtain subject incisional biopsy inguinal LN pinch biopsy ileum rectum via colonoscopy . The select LT-enhanced ARV regimen initiate . Participants return clinic week 2 4 monthly safety evaluation , CD4 T cell count , plasma HIV-RNA ARV drug concentration plasma PBMCs . An intensive PK study perform week 2 . At month 3 6 , inguinal LN biopsy pinch biopsy ileum rectum repeat .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Anti-HIV Agents</mesh_term>
	<criteria>1 . Antiretroviral drug ( ARV ) naive , HIVinfected individual 2 . Aged 18 year 3 . Agree initiate ARV therapy 4 . BMI ≤ 30 5 . Inguinal lymph node ( ) identifiable ultrasound enrollment 6 . Screening plasma HIV RNA &gt; 40,000 copies/mL 7 . Screening CD4 count &gt; 200 cells/mm3 8 . Women child bear potential must agree use effective contraception study . 9 . Screening viral isolates demonstrate genotype sensitivity choose antiretroviral therapy ( ART ) regimen . 10 . Able provide voluntary write consent 1 . Previous ARV therapy 2 . Contraindications ARV regimen ( e.g. , comorbid condition drug interaction ) , study procedure determine principal investigator . 3 . Planning current pregnancy breastfeed 4 . History and/or presence clinically significant disease disorder , cardiovascular , pulmonary , renal , hepatic , neurological , gastrointestinal psychiatric/mental disease/disorder , , opinion enrol physician , may put participant risk participation study , influence result study , affect participant 's ability participate study . 5 . Inability comply study procedure per enrol physician discretion</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
</DOC>